Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.31 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13801388 | 0.82 | HTR2A (0.40) | HTR2AHTR2CHTR2BAKR1C3AKR1C2 | |
| SCHEMBL13547711 | 0.82 | HTR2A (0.34) | HTR2AHTR2CHTR2BAKR1C3AKR1C2 | |
| SCHEMBL2737355 | 0.80 | LMNA (0.41) | HTR2AHTR2CHTR2BLMNATRPA1 | |
| SCHEMBL12534593 | 0.80 | HTR2A (0.33) | HTR2AHTR2CHTR2BAKR1C3AKR1C2 | |
| SCHEMBL15934961 | 0.79 | HTR2A (0.36) | HTR2AHTR2CHTR2BAKR1C3AKR1C2 | |
| SCHEMBL22155235 | 0.78 | HTR2A (0.38) | HTR2AHTR2CHTR2BAKR1C3AKR1C2 | |
| SCHEMBL15934967 | 0.78 | ADRB2 (0.38) | HTR2AHTR2CHTR2BAKR1C3AKR1C2 | |
| SCHEMBL26712843 | 0.77 | CYP1A2 (0.35) | HTR2AHTR2CHTR2BAKR1C3AKR1C2 | |
| SCHEMBL12552644 | 0.76 | HTR2A (0.37) | HTR2AHTR2CHTR2BAKR1C3AKR1C2 | |
| SCHEMBL12144344 | 0.76 | HTR2A (0.36) | HTR2AHTR2CHTR2BAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2022-05-03 | — | — | US | disclosed |
| US-11174250-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2021-11-16 | — | — | US | disclosed |
| WO-2021221208-A1 | DIHYDROPYRANO[3,2-G]CROMEN-2-ONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME AS ACTIVE INGREDIENT | 재단법인 대구경북첨단의료산업진흥재단 (KR) | 2021-11-04 | — | — | WO | disclosed |
| US-10428049-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190119264-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-20190112290-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-04-18 | — | — | US | disclosed |
| US-20190016701-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-9951046-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2018-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | HTR2A 3796/4885HTR2C 3554/4885HTR2B 4177/4885 |
| US-11174250-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | HTR2A 3840/4885HTR2C 3659/4885HTR2B 4205/4885 |
| US-20190119264-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | HTR2A 4408/4885HTR2C 4499/4885HTR2B 4661/4885 |
| US-10428049-B2 | TRPA1 modulators | TRPA1, TRPV1, TRPV2 | HTR2A 73/4885HTR2C 75/4885HTR2B 88/4885 |
| US-20190016701-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | HTR2A 73/4885HTR2C 75/4885HTR2B 88/4885 |
| US-20190112290-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | HTR2A 4433/4885HTR2C 4443/4885HTR2B 4647/4885 |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | HTR2A 3796/4885HTR2C 3554/4885HTR2B 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.